Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study
Annalisa Ruggeri,Nicole Santoro,Jacques-Emmanuel Galimard,Krzysztof Kalwak,Mattia Algeri,Ludmila Zubarovskaya,Krzysztof Czyzewski,Elena Skorobogatova,Petr Sedlacek,Caroline Besley,Adriana Balduzzi,Yves Bertrand,Julia Peristeri,Franca Fagioli,Mariane Ifversen,Jolanta Gozdzik,Christina Peters,Birgitta Versluijs,Alessandra Biffi,Arcangelo Prete,Maura Faraci,Ibrahim Ghemlas,Ivana Bodova,Olga Aleinikova,Arnaud Dalissier,Vanderson Rocha,Selim Corbacioglu
DOI: https://doi.org/10.3324/haematol.2023.284445
2024-01-09
Haematologica
Abstract:In children with acute myeloid leukemia (AML) who lack an HLA identical sibling, the donor can be replaced with an HLA matched unrelated donor (MUD) or a haploidentical donor (haplo). We compared outcomes of patients <18 years with AML in first and second complete remission (CR1 and CR2) undergoing a hematopoietic stem cell transplantation (HCT) either with a MUD with anti-thymocyte globuline (ATG) (n=420) or a haplo HCT with PT-CY (n=96) after a myeloablative conditioning regimen (MAC) between...
hematology
What problem does this paper attempt to address?